SARASOTA, Fla., March 24,
2022 /PRNewswire/ -- INVO Bioscience, Inc.
(NASDAQ: INVO), developers of the INVOcell®, an
advanced fertility treatment technology which is currently
available, is exhibiting the INVOcell solution at the 2022 Pacific
Coast Reproductive Society (PCRS) Annual Meeting, taking place
March 23-27 at the Renaissance
Esmeralda Resort & Spa in Indian
Wells, CA.
Chris Myer, INVO's Senior VP,
Business Development, Americas, and Bojan
(Bo) Mitrovic, PhD, INVO's Director, Sales, US will both be
available in Booth #314 discussing INVOcell with the broader
Assisted Reproductive Technology (ART) physician community.
Steve Shum, CEO of INVO
Bioscience, commented, "A key component to our go forward
commercialization strategy is to synchronize and take an expanded,
more comprehensive and direct approach toward our U.S. efforts.
PCRS provides us an opportunity to easily connect with a number of
U.S. IVF clinics that have already trained on the INVOcell device
and the IVC treatment process, as well as introduce our solution to
additional clinic operators interested in expanding their treatment
options and overall capacity by introducing INVOcell to
patients."
Pacific Coast Reproductive Society is a multidisciplinary
medical specialty society providing Continuing Medical Education
(CME) to physicians and allied healthcare professionals. The PCRS
Annual Meeting provides an outstanding forum for the exchange of
information and the advancement of the ideologies of reproductive
medicine in a relaxed and collegial setting. Session topics have
been carefully selected to bring you the highest quality,
innovative CME, designed and presented by thought leaders in
reproductive medicine.
About INVO Bioscience
We are a commercial-stage fertility company expanding access to
advanced treatment worldwide. Our primary mission is to implement
new medical technologies aimed at increasing the availability of
affordable, high-quality, patient-centered fertility care. Our
patented medical device, the INVOcell®, enables a
revolutionary in vivo method of vaginal incubation. This
treatment solution is the world's first intravaginal culture
technique for the incubation of oocytes and sperm during
fertilization and early embryo development. This technique,
designated as "IVC," provides patients a more natural and intimate
experience in comparison to other assisted reproductive technology
(ART) treatments. The IVC procedure can deliver comparable results
at a fraction of the cost of traditional in vitro
fertilization (IVF) and is a significantly more effective treatment
than intrauterine insemination (IUI). Our commercialization
strategy involves the opening of dedicated INVO Centers focused on
offering the INVOcell® and IVC procedure (with 3 centers
in North America now operational),
as well as selling our technology solution into existing fertility
clinics. For more information, please visit
www.invobio.com.
Safe Harbor Statement
This release includes forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
The Company invokes the protections of the Private Securities
Litigation Reform Act of 1995. All statements regarding our
expected future financial position, results of operations, cash
flows, financing plans, business strategies, products and services,
competitive positions, growth opportunities, plans and objectives
of management for future operations, as well as statements that
include words such as "anticipate," "if," "believe," "plan,"
"estimate," "expect," "intend," "may," "could," "should," "will,"
and other similar expressions are forward-looking statements. All
forward-looking statements involve risks, uncertainties and
contingencies, many of which are beyond our control, which may
cause actual results, performance, or achievements to differ
materially from anticipated results, performance, or achievements.
Factors that may cause actual results to differ materially from
those in the forward-looking statements include those set forth in
our filings at www.sec.gov. We are under no obligation to
(and expressly disclaim any such obligation to) update or alter our
forward-looking statements, whether as a result of new information,
future events or otherwise.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/invo-bioscience-to-exhibit-at-the-2022-pacific-coast-reproductive-society-pcrs-annual-meeting-301509640.html
SOURCE INVO Bioscience, Inc.